Millions of Americans are infected with human papillomavirus (HPV), with rates of HPV-positive head and neck cancer (HNC) expected to surpass cervical cancer by 2020.
; thus, physicians must be educated about the association between HPV and HNC. Studies suggest that only 47% of pediatricians routinely discuss HPVpositive HNC owing to a self-reported lack of knowledge.
7 It becomes imperative to examine how we are training our next generation of physicians regarding this epidemic. We examined knowledge about HPV-positive cancer among New York State medical students to determine whether there is an educational gap in HNC knowledge.
Methods | A survey administered through REDCap (https: //projectredcap.org) collected information on level of training, objective HPV-positive cancer knowledge, and selfassessment of knowledge. Surveys were sent to medical students at 10 medical schools in New York State via representatives at each institution, with 1 reminder email sent to each representative. Because we did not track responses by school or official distribution by representatives, we could not determine response rates. Objective knowledge was assessed using 2 knowledge-based questions. Self-assessment of knowledge was obtained using a 5-point Likert scale, from 1, representing no knowledge, to 5, representing excellent Figure 1A with year of training breakdown in Figure 1B Figure 1C . Compared with cervical cancer, self-reported knowledge scores were lower for HNC (mean difference, 1.47; 95% CI, 1.36-1.58; Cohen d = 1.53) and RRP (mean difference, 2.03; 95% CI, 1.93-2.12; Cohen d = 2.27). The magnitude of difference was smaller compared with the next highest reported score, anal cancer (mean difference vs HNC, 1.19; 95% CI, 1.07-1.31; Cohen d = 1.15; mean difference vs RRP, 1.75; 95% CI, 1.64-1.85; Cohen d = 1.75). Likert data are summarized in Figure 2 . Discussion | Our data suggest an educational gap about HPVpositive cancers among medical students. Despite clear awareness of cervical cancer risks, fewer students are aware of HPV's head and neck manifestations. Only about half of medical students graduate with knowledge about this association. Although this study is limited by its low response rate (617 students) relative to the total number of medical students in New York state, this education gap may be generalizable to students nationally. To increase HPV vaccination rates and have an impact on the future of this epidemic, physicians must be informed; thus, head and neck manifestations of persistent HPV infection should be emphasized in medical school curricula. 
Opioid Prescription Patterns Among Patients With Head and Neck Cancer
Head and neck cancer (HNCA) pain represents a significant physical, psychological, and financial burden for patients. 1 Opioids remain a mainstay of treatment for these patients, and head and neck oncologists must balance the goal of optimal pain control with the risks of abuse. MEPS is a nationally representative survey of households conducted annually by the Agency for Healthcare Research and Quality that provides an assessment of health care utilization. Every other year was selected, given sampling period of 2 years per published data set. Massachusetts Eye and Ear Infirmary exempted the study from institutional review board approval. The database was queried for all prescription events associated with an existing diagnosis of HNCA (Clinical Classification Software [CCS] code 011), as well as lung cancer (CCS 019) and colon cancer (CCS 014). The proportion of prescriptions that were opioids, mean payment per opioid prescription, duration of supply, and quantity of opioid prescribed were quantified and compared between HNCA and LCCA cohorts.
Effect sizes were calculated using standardized difference for means (Cohen d) and odds ratio for proportions.
Results | A total of 739 prescriptions associated with HNCA (n = 168) and LCCA (n = 571) diagnoses during the study period were identified and included in the analysis. Patients with HNCA were at significantly greater odds of being prescribed an opioid than patients with LCCA (odds ratio [OR], 1.68; 95% CI, 1.13-2.49). In addition, a greater quantity of oxycodone tablets was provided per prescription for HNCA (mean [SD], 87.1 [82.4] tablets) compared with LCCA (mean [SD], 71.0 [56.3] tablets), although the standardized mean difference was highly variable (Cohen d = 0.25; 95% CI, −10.9 to 11.36). There was no difference in mean duration of supply or mean payment per opioid prescription between the 2 groups (Table) .
Discussion | Head and neck cancer diagnoses were associated with significantly greater odds of opioid prescription. Data suggest that patients with HNCA have a higher prevalence of pain than patients with other cancer types, which may explain a necessity for more intensive pain management regimens.
2 In a study of patients undergoing surgery for oral cancer, longterm use of opioids was associated with significantly decreased disease-free survival. 3 Furthermore, there is a significant correlation between physician prescribing patterns and risk of overdose among patients with cancer receiving opioid therapy. 4 Indeed, opiate use is not without risk, and achieving adequate pain management while minimizing the risk of substance overuse and misuse is critical. It is imperative that head and neck cancer physicians are mindful of opioid prescription trends for patients with HNCA, especially in the context of the current opioid epidemic. This study provides preliminary insight into opioid prescription behaviors; however, it is limited by the absence of prior oncologic treatment, tumor stage, and location, as well as comorbid chronic pain conditions. There is an urgent need for further quantification and understanding of postprocedural and chronic opioid use in this patient population. 
